Ubiquitin-fold modifier 1 acts as a positive regulator of breast cancer

Frontiers in Endocrinology

Volumn 6, Issue MAR, 2015, Pages

  Yoo, Hee Min ^a   Park, Jong Ho ^a   Jeon, Young Joo ^a   Chung, Chin Ha ^a  

^a Seoul National University   (South Korea)

Author keywords

ASC1; Breast cancer; ER ; Post translational modification; UFM1

Indexed keywords

ACTIVATING SIGNAL COINTEGRATOR 1; ADENOSINE TRIPHOSPHATE; CYCLIN D1; DEUBIQUITINASE; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEDD8 PROTEIN; NERVE CELL ADHESION MOLECULE; PROTEIN; SUMO 2 PROTEIN; SUMO PROTEIN; UBIQUITIN ACTIVATING ENZYME 5; UBIQUITIN FOLD MODIFIER 1; UBIQUITIN FOLD MODIFIER CONJUGATING ENZYME 1; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UBIQUITINATED PROTEIN; UFM1 BINDING PROTEIN 1; UFM1 SPECIFIC PEPTIDASE 1; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CARCINOGENESIS; CONJUGATION; ESTROGEN RESPONSIVE ELEMENT; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; MCF 7 CELL LINE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN ACETYLATION; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; TRANSACTIVATION ASSAY; TRANSCRIPTION INITIATION; TRANSESTERIFICATION; UFMYLATION;

EID: 84926669715     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00036     Document Type: Article

References (48)

1. Jeon YJ, Yoo HM, Chung CH. ISG15 and immune diseases. Biochim Biophys Acta (2010) 1802:485-96. doi: 10.1016/j.bbadis.2010.02.006
2. Flotho A, Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem (2013) 82:357-85. doi:10.1146/annurev-biochem-061909-093311
3. Geoffroy M-C, Hay RT. An additional role for SUMO in ubiquitin-mediated proteolysis. Nat Rev Mol Cell Biol (2009) 10:564-8. doi:10.1038/nrm2707
4. Hoeller D, Hecker C-M, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer (2006) 6:776-88. doi:10.1038/nrc1994
5. Komatsu M, Chiba T, Tatsumi K, Iemura S, Tanida I, Okazaki N, et al. A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J (2004) 23:1977-86. doi:10.1038/sj.emboj.7600205
6. Daniel J, Liebau E. The ufm1 cascade. Cells (2014) 3:627-38. doi:10.3390/cells3020627
7. Zhou W, Slingerland JM. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer (2014) 14:26-38. doi:10.1038/nrc3622
8. Shao W, Keeton EK, McDonnell DP, Brown M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc Natl Acad Sci U S A (2004) 101:11599-604. doi:10.1073/pnas.0402997101
9. Xu J, Wu R-C, O'Malley BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer (2009) 9:615-30. doi:10.1038/nrc2695
10. Hassig A, Schreiberi SL. Nuclear histone acetylases and deacetylases regulation: HATS off to HDACs. Curr Opin Chem Biol (1997) 1:300-8. doi:10.1016/S1367-5931(97)80066-X
11. Lee DY, Teyssier C, Strahl BD, Stallcup MR. Role of protein methylation in regulation of transcription. Endocr Rev (2005) 26:147-70. doi:10.1210/er.2004-0008
12. Lonard DM, O'malley BW. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell (2007) 27:691-700. doi:10.1016/j.molcel.2007.08.012
13. Lee JW, Choi HS, Gyuris J, Brent R, Moore DD. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol Endocrinol (1995) 9:243-54. doi:10.1210/mend.9.2.7776974
14. Kim HJ, Yi JY, Sung HS, Moore DD, Jhun BH, Lee YC, et al. Activating signal cointegrator 1, a novel transcription coactivator of nuclear receptors, and its cytosolic localization under conditions of serum deprivation. Mol Cell Biol (1999) 19:6323-32.
15. Lee YS. Activating signal cointegrator 1 is highly expressed in murine testicular Leydig cells and enhances the ligand-dependent transactivation of androgen receptor. Biol Reprod (2002) 67:1580-7. doi:10.1095/biolreprod.102.006155
16. Jung D, Sung H, Goo Y, Lee HM, Park OK, Jung S, et al. Novel transcription coactivator complex containing activating signal cointegrator 1. Mol Cell Biol (2002) 22:5203-11. doi:10.1128/MCB.22.14.5203-5211.2002
17. Sasakawa H, Sakata E, Yamaguchi Y, Komatsu M, Tatsumi K, Kominami E, et al. Solution structure and dynamics of Ufm1, a ubiquitin-fold modifier 1. Biochem Biophys Res Commun (2006) 343:21-6. doi:10.1016/j.bbrc.2006.02.107
18. Schulman BA, Harper JW. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol (2009) 10:319-31. doi:10.1038/nrm2673
19. Bacik J-P, Walker JR, Ali M, Schimmer AD, Dhe-Paganon S. Crystal structure of the human ubiquitin-activating enzyme 5 (UBA5) bound to ATP: mechanistic insights into a minimalistic E1 enzyme. J Biol Chem (2010) 285:20273-80. doi:10.1074/jbc.M110.102921
20. Zheng M, Gu X, Zheng D, Yang Z, Li F, Zhao J, et al. UBE1DC1, an ubiquitin-activating enzyme, activates two different ubiquitin-like proteins. J Cell Biochem (2008) 104:2324-34. doi:10.1002/jcb.21791
21. Tatsumi K, Yamamoto-Mukai H, Shimizu R, Waguri S, Sou Y-S, Sakamoto A, et al. The Ufm1-activating enzyme Uba5 is indispensable for erythroid differentiation in mice. Nat Commun (2011) 2:181. doi:10.1038/ncomms1182
22. Yoo HM, Kang SH, Kim JY, Lee JE, Seong MW, Lee SW, et al. Modification of ASC1 by UFM1 is crucial for ERa transactivation and breast cancer development. Mol Cell (2014) 56:261-74. doi:10.1016/j.molcel.2014.08.007
23. Liu G, Forouhar F, Eletsky A, Atreya HS, Aramini JM, Xiao R, et al. NMR and X-RAY structures of human E2-like ubiquitin-fold modifier conjugating enzyme 1 (UFC1) reveal structural and functional conservation in the metazoan UFM1-UBA5-UFC1 ubiquination pathway. J Struct Funct Genomics (2009) 10:127-36. doi:10.1007/s10969-008-9054-7
24. Homrich M, Wobst H, Laurini C, Sabrowski J, Schmitz B, Diestel S. Cytoplasmic domain of NCAM140 interacts with ubiquitin-fold modifier-conjugating enzyme-1 (Ufc1). Exp Cell Res (2014) 324:192-9. doi:10.1016/j.yexcr.2014.04.003
25. Shiwaku H, Yoshimura N, Tamura T, Sone M, Ogishima S, Watase K, et al. Suppression of the novel ER protein Maxer by mutant ataxin-1 in Bergman glia contributes to non-cell-autonomous toxicity. EMBO J (2010) 29:2446-60. doi:10.1038/emboj.2010.116
26. Tatsumi K, Sou Y, Tada N, Nakamura E, Iemura S, Natsume T, et al. A novel type of E3 ligase for the Ufm1 conjugation system. J Biol Chem (2010) 285:5417-27. doi:10.1074/jbc.M109.036814
27. Wu J, Lei G, Mei M, Tang Y, Li H. A novel C53/LZAP-interacting protein regulates stability of C53/LZAP and DDRGK domain-containing protein 1 (DDRGK1) and modulates NF-kappaB signaling. J Biol Chem (2010) 285:15126-36. doi:10.1074/jbc.M110.110619
28. Ha BH, Ahn H-C, Kang SH, Tanaka K, Chung CH, Kim EEK. Structural basis for Ufm1 processing by UfSP1. J Biol Chem (2008) 283:14893-900. doi:10.1074/jbc.M708756200
29. Ha BH, Jeon YJ, Shin SC, Tatsumi K, Komatsu M, Tanaka K, et al. Structure of ubiquitin-fold modifier 1-specific protease UfSP2. J Biol Chem (2011) 286:10248-57. doi:10.1074/jbc.M110.172171
30. Jiang H, Luo S, Li H. Cdk5 activator-binding protein C53 regulates apoptosis induced by genotoxic stress via modulating the G2/M DNA damage checkpoint. J Biol Chem (2005) 280:20651-9. doi:10.1074/jbc.M413431200
31. Wang J, An H, Mayo MW, Baldwin AS, Yarbrough WG. LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell (2007) 12:239-51. doi:10.1016/j.ccr.2007.07.002
32. Wang J, He X, Luo Y, Yarbrough WG. A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2. Biochem J (2006) 393:489-501. doi:10.1042/BJ20050960
33. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, et al. Mechanisms of estrogen action. Physiol Rev (2001) 81:1535-65.
34. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res (2001) 29:2905-19. doi:10.1093/nar/29.14.2905
35. Umar A, Dunn BK, Greenwald P. Future directions in cancer prevention. Nat Rev Cancer (2012) 12:835-48. doi:10.1038/nrc3397
36. Jozwik KM, Carroll JS. Pioneer factors in hormone-dependent cancers. Nat Rev Cancer (2012) 12:381-5. doi:10.1038/nrc3263
37. Beelen K, Zwart W, Linn SC. Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol (2012) 9:529-41. doi:10.1038/nrclinonc.2012.121
38. Nilsson S, Koehler KF, Gustafsson J-Å. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov (2011) 10:778-92. doi:10.1038/nrd3551
39. Li BC, Chan WY, Li CY, Chow C, Ng EK, Chung SC. Allelic loss of chromosome 6q in gastric carcinoma. Diagn Mol Pathol (2003) 12:193-200. doi:10.1097/00019606-200312000-00003
40. Lu T, Hano H. Deletion at chromosome arms 6q16-22 and 10q22.3-23.1 associated with initiation of prostate cancer. Prostate Cancer Prostatic Dis (2008) 11:357-61. doi:10.1038/pcan.2008.4
41. Saito S, Ghosh M, Morita K, Hirano T. The genetic differences between gallbladder and bile duct cancer cell lines. Oncol Rep (2006) 16:949-56. doi:10.3892/or.16.5.949
42. Kim CH, Nam H-S, Lee EH, Han SH, Cho HJ, Chung HJ, et al. Overexpression of a novel regulator of p120 catenin, NLBP, promotes lung adenocarcinoma proliferation. Cell Cycle (2013) 12:2443-53. doi:10.4161/cc.25451
43. Xi P, Ding D, Zhou J, Wang M, Cong Y-S. DDRGK1 regulates NF-κB activity by modulating IκBα stability. PLoS One (2013) 8:e64231. doi:10.1371/journal.pone.0064231
44. Lee Y, Johnson KR, Hallenbeck JM. Global protein conjugation by ubiquitin-like-modifiers during ischemic stress is regulated by microRNAs and confers robust tolerance to ischemia. PLoS One (2012) 7:e47787. doi:10.1371/journal.pone.0047787
45. Zhang Y, Zhang M, Wu J, Lei G, Li H. Transcriptional regulation of the Ufm1 conjugation system in response to disturbance of the endoplasmic reticulum homeostasis and inhibition of vesicle trafficking. PLoS One (2012) 7:e48587. doi:10.1371/journal.pone.0048587
46. Lu H, Yang Y, Allister EM, Wijesekara N, Wheeler MB. The identification of potential factors associated with the development of type 2 diabetes: a quantitative proteomics approach. Mol Cell Proteomics (2008) 7:1434-51. doi:10.1074/mcp.M700478-MCP200
47. Azfer A, Niu J, Rogers LM, Adamski FM, Kolattukudy PE. Activation of endoplasmic reticulum stress response during the development of ischemic heart disease. Am J Physiol Heart Circ Physiol (2006) 291:H1411-20. doi:10.1152/ajpheart.01378.2005
48. Lemaire K, Moura RF, Granvik M, Igoillo-Esteve M, Hohmeier HE, Hendrickx N, et al. Ubiquitin fold modifier 1 (UFM1) and its target UFBP1 protect pancreatic beta cells from ER stress-induced apoptosis. PLoS One (2011) 6:e18517. doi:10.1371/journal.pone.0018517